Hidemi Nakagawa

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 10

Top Topics

Atopic Dermatitis

Top Venues

Dermatology and therapy

The Journal of dermatology

Journal of immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatology and therapy 13 (3) (2023)
Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatology and therapy 13 (3) (2023)
Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatology and therapy (2023)
Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatology and therapy 13 (3) (2023)
Akihiko Asahina, Yukari Okubo, Akimichi Morita, Yayoi Tada, Atsuyuki Igarashi, Richard G Langley, Delphine Deherder, Mizuho Matano, Veerle Vanvoorden, Maggie Wang, Mamitaro Ohtsuki, Hidemi Nakagawa
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatology and therapy (2023)
Atsuyuki Igarashi, Hidemi Nakagawa, Akimichi Morita, Yukari Okubo, Shigetoshi Sano, Shinichi Imafuku, Yayoi Tada, Masaru Honma, Alan M Mendelsohn, Masaki Kawamura, Mamitaro Ohtsuki
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1). The Journal of dermatology 48 (6) (2021)
Shinichi Imafuku, Hidemi Nakagawa, Atsuyuki Igarashi, Akimichi Morita, Yukari Okubo, Shigetoshi Sano, Yayoi Tada, Osamu Nemoto, Stephen J Rozzo, Masaki Kawamura, Mamitaro Ohtsuki
Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1). The Journal of dermatology 48 (6) (2021)
Yukie Yamaguchi, Yasumasa Kanai, Hiroki Kitabayashi, Hiroki Okada, Hidemi Nakagawa
Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis. The Journal of dermatology 48 (3) (2020)
Hidetoshi Takahashi, Hiroyasu Katayama, Yuta Uwajima, Masato Koda, Hajime Sasaki, Katsumi Tanito, Masanori Hagiwara, Koma Matsuo, Hidemi Nakagawa
Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence. The Journal of dermatology 47 (11) (2020)
Norie Aizawa, Yozo Ishiuji, Mitsutoshi Tominaga, Sanae Sakata, Nobuaki Takahashi, Koichi Yanaba, Yoshinori Umezawa, Akihiko Asahina, Utako Kimura, Yasushi Suga, Kenji Takamori, Hidemi Nakagawa
Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis. Journal of immunology research 2019 (2019)